Antimicrobial resistance, leading to the development of superbugs, is a major threat to public health and continues to increase as a problem, due to continued misuse of antibiotics. With pharmaceutical companies showing less focus on the development of new antibiotics, several incentive initiatives have been set up – CARBX, BARDA, IMI (EU) – in order to encourage reinvestments. From a governmental point of view, the challenge lies in encouraging companies to develop new antimicrobial drugs and to strengthen and maintain the pipeline of antibiotics and other antimicrobials currently being developed.
To address the ever-growing need of informative and thought-provoking discussions,Superbugs &Superdrugs USA conference will offer a jam-packed agenda with presentations from key industry leaders and up-and-coming thinkers, within the field.
This years’ Superbugs &Superdrugs USA conference programme will help participants to learn about pathogen focused drug development; discover the best methods to overcome bacterial resistance through novel modes of action; discuss the state of developments within the antifungal space; develop an understanding of funding opportunities which support antibacterial research and development; gain insight into new techniques through case-study examples of rapid diagnostic methods currently being used within the field, making this event the perfect platform to strengthen knowledge in key principles.
Plus, topical workshops on November 14:
Further details at http://www.superbugs-usa.com/phhqWL
+44 (0)20 7827 6000
© 2018 PHARMA NEWS HQ, All rights reserved
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.